Search Results - "Newsome, Philip N"

Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease by Khan, Reenam S., Bril, Fernando, Cusi, Kenneth, Newsome, Philip N.

“…Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general population, and cirrhosis secondary to nonalcoholic steatohepatitis…”
Get full text

A concise review of non-alcoholic fatty liver disease by Than, Nwe Ni, Newsome, Philip N

“…Abstract Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and the incidence of which is rising rapidly due to…”
Get full text

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis by Newsome, Philip N, Buchholtz, Kristine, Cusi, Kenneth, Linder, Martin, Okanoue, Takeshi, Ratziu, Vlad, Sanyal, Arun J, Sejling, Anne-Sophie, Harrison, Stephen A

“…Patients with nonalcoholic steatohepatitis were randomly assigned to receive subcutaneous semaglutide or placebo. The incidence of NASH resolution was…”
Get full text

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement by Eslam, Mohammed, Newsome, Philip N., Sarin, Shiv K., Anstee, Quentin M., Targher, Giovanni, Romero-Gomez, Manuel, Zelber-Sagi, Shira, Wai-Sun Wong, Vincent, Dufour, Jean-François, Schattenberg, Jörn M., Kawaguchi, Takumi, Arrese, Marco, Valenti, Luca, Shiha, Gamal, Tiribelli, Claudio, Yki-Järvinen, Hannele, Fan, Jian-Gao, Grønbæk, Henning, Yilmaz, Yusuf, Cortez-Pinto, Helena, Oliveira, Claudia P., Bedossa, Pierre, Adams, Leon A., Zheng, Ming-Hua, Fouad, Yasser, Chan, Wah-Kheong, Mendez-Sanchez, Nahum, Ahn, Sang Hoon, Castera, Laurent, Bugianesi, Elisabetta, Ratziu, Vlad, George, Jacob

“…The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic…”
Get full text

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper by Boettler, Tobias, Newsome, Philip N., Mondelli, Mario U., Maticic, Mojca, Cordero, Elisa, Cornberg, Markus, Berg, Thomas

“…The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with…”
Get full text

Guidelines on the management of abnormal liver blood tests by Newsome, Philip N, Cramb, Rob, Davison, Suzanne M, Dillon, John F, Foulerton, Mark, Godfrey, Edmund M, Hall, Richard, Harrower, Ulrike, Hudson, Mark, Langford, Andrew, Mackie, Anne, Mitchell-Thain, Robert, Sennett, Karen, Sheron, Nicholas C, Verne, Julia, Walmsley, Martine, Yeoman, Andrew

“…These updated guidelines on the management of abnormal liver blood tests have been commissioned by the Clinical Services and Standards Committee (CSSC) of the…”
Get more information

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study by Armstrong, Matthew James, PhD, Gaunt, Piers, MSc, Aithal, Guruprasad P, PhD, Barton, Darren, BSc, Hull, Diana, MSc, Parker, Richard, MBChB, Hazlehurst, Jonathan M, MBChB, Guo, Kathy, MSc, Abouda, George, MBChB, Aldersley, Mark A, PhD, Stocken, Deborah, PhD, Gough, Stephen C, Prof, Tomlinson, Jeremy W, Prof, Brown, Rachel M, MBChB, Hübscher, Stefan G, Prof, Newsome, Philip N, Prof

“…Summary Background Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis, concentrations of liver enzymes, and insulin resistance in murine models…”
Get full text

Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells by de Witte, Samantha F.H., Luk, Franka, Sierra Parraga, Jesus M., Gargesha, Madhu, Merino, Ana, Korevaar, Sander S., Shankar, Anusha S., O'Flynn, Lisa, Elliman, Steve J., Roy, Debashish, Betjes, Michiel G.H., Newsome, Philip N., Baan, Carla C., Hoogduijn, Martin J.

“…Mesenchymal stem or stromal cells (MSC) are under investigation as a potential immunotherapy. MSC are usually administered via intravenous infusion, after…”
Get full text

Non-alcoholic fatty liver disease and the interface between primary and secondary care by Tsochatzis, Emmanuel A, Newsome, Philip N

“…Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25-30% in unselected populations and has become the main reason for referrals to hepatology…”
Get more information

A Comparison of Phenotypic and Functional Properties of Mesenchymal Stromal Cells and Multipotent Adult Progenitor Cells by Khan, Reenam S, Newsome, Philip N

“…Both Multipotent Adult Progenitor Cells and Mesenchymal Stromal Cells are bone-marrow derived, non-haematopoietic adherent cells, that are well-known for…”
Get full text

Patient and public perspectives on cell and gene therapies: a systematic review by Aiyegbusi, Olalekan Lee, Macpherson, Karen, Elston, Lauren, Myles, Susan, Washington, Jennifer, Sungum, Nisha, Briggs, Mark, Newsome, Philip N., Calvert, Melanie J.

“…Cell and gene therapies offer opportunities for treating disease with potential to restore function, and cure disease. However, they are not without risk and…”
Get full text

Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation? by Owen, Andrew, Newsome, Philip N

“…In response to the global burden of liver disease there has been a commensurate increase in the demand for liver transplantation. However, due to a paucity of…”
Get full text

Non-alcoholic fatty liver disease and liver transplantation by Khan, Reenam S, Newsome, Philip N

“…Summary Cirrhosis secondary to non-alcoholic steatohepatitis (NASH) is a common indication for liver transplant. In comparison to other cirrhotic patients,…”
Get full text

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic by Boettler, Tobias, Marjot, Thomas, Newsome, Philip N., Mondelli, Mario U., Maticic, Mojca, Cordero, Elisa, Jalan, Rajiv, Moreau, Richard, Cornberg, Markus, Berg, Thomas

“…During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID published a position paper to provide guidance for physicians…”
Get full text

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis by Sanyal, Arun J., Ratziu, Vlad, Loomba, Rohit, Anstee, Quentin M., Kowdley, Kris V., Rinella, Mary E., Sheikh, Muhammad Y., Trotter, James F., Knapple, Whitfield, Lawitz, Eric J., Abdelmalek, Manal F., Newsome, Philip N., Boursier, Jérôme, Mathurin, Philippe, Dufour, Jean-François, Berrey, M. Michelle, Shiff, Steven J., Sawhney, Sangeeta, Capozza, Thomas, Leyva, Rina, Harrison, Stephen A., Younossi, Zobair M.

“…Obeticholic acid (OCA) is a first-in-class farnesoid X receptor agonist and antifibrotic agent in development for the treatment of pre-cirrhotic liver fibrosis…”
Get full text

3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo by Rashidi, Hassan, Luu, Nguyet-Thin, Alwahsh, Salamah M., Ginai, Maaria, Alhaque, Sharmin, Dong, Hua, Tomaz, Rute A., Vernay, Bertrand, Vigneswara, Vasanthy, Hallett, John M., Chandrashekran, Anil, Dhawan, Anil, Vallier, Ludovic, Bradley, Mark, Callanan, Anthony, Forbes, Stuart J., Newsome, Philip N., Hay, David C.

“…Liver disease is an escalating global health issue. While liver transplantation is an effective mode of therapy, patient mortality has increased due to the…”
Get full text

Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort by Armstrong, Matthew J, Houlihan, Diarmaid D, Bentham, Louise, Shaw, Jean C, Cramb, Robert, Olliff, Simon, Gill, Paramjit S, Neuberger, James M, Lilford, Richard J, Newsome, Philip N

“…Background & Aims Non-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal LFTs in primary care, but there are no data defining its contribution…”
Get full text

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial by Newsome, Philip N, Sanyal, Arun J, Engebretsen, Kristiane A, Kliers, Iris, Østergaard, Laura, Vanni, Denise, Bugianesi, Elisabetta, Rinella, Mary E, Roden, Michael, Ratziu, Vlad

“…Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction-associated steatohepatitis…”
Get full text

Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests by Boursier, Jérôme, Roux, Marine, Costentin, Charlotte, Chaigneau, Julien, Fournier-Poizat, Céline, Trylesinski, Aldo, Canivet, Clémence M., Michalak, Sophie, Le Bail, Brigitte, Paradis, Valérie, Bedossa, Pierre, Sturm, Nathalie, de Ledinghen, Victor, Newsome, Philip N.

“…Unlike for advanced liver fibrosis, the practical rules for the early non-invasive diagnosis of cirrhosis in NAFLD remain not well defined. Here, we report the…”
Get full text

The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation by Knoblich, Konstantin, Cruz Migoni, Sara, Siew, Susan M, Jinks, Elizabeth, Kaul, Baksho, Jeffery, Hannah C, Baker, Alfie T, Suliman, Muath, Vrzalikova, Katerina, Mehenna, Hisham, Murray, Paul G, Barone, Francesca, Oo, Ye H, Newsome, Philip N, Hirschfield, Gideon, Kelly, Deirdre, Lee, Steven P, Parekkadan, Biju, Turley, Shannon J, Fletcher, Anne L

“…The microenvironment of lymphoid organs can aid healthy immune function through provision of both structural and molecular support. In mice, fibroblastic…”
Get full text